Evercore ISI Lowers Savara (NASDAQ:SVRA) Price Target to $7.00

Savara (NASDAQ:SVRA - Get Free Report) had its price target dropped by stock analysts at Evercore ISI from $10.00 to $7.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Evercore ISI's price objective would suggest a potential upside of 48.31% from the company's current price.

Several other analysts have also weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $6.00 target price on shares of Savara in a research report on Monday. Piper Sandler boosted their target price on Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. Finally, JMP Securities reissued a "market outperform" rating and issued a $8.00 price objective on shares of Savara in a research note on Monday, May 6th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara has an average rating of "Buy" and an average target price of $8.00.

Savara Trading Down 2.3 %

Savara stock traded down $0.11 during mid-day trading on Thursday, hitting $4.72. 457,623 shares of the stock were exchanged, compared to its average volume of 862,136. The firm's fifty day simple moving average is $4.84 and its two-hundred day simple moving average is $4.57. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. Savara has a 12 month low of $2.16 and a 12 month high of $5.70. The stock has a market capitalization of $652.26 million, a price-to-earnings ratio of -12.81 and a beta of 0.73.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Analysts forecast that Savara will post -0.38 EPS for the current year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara in the 1st quarter worth $35,000. AJOVista LLC bought a new position in Savara in the 4th quarter valued at $40,000. Principal Financial Group Inc. purchased a new stake in shares of Savara during the 3rd quarter valued at $48,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Savara during the 3rd quarter valued at $64,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Savara during the 4th quarter worth $74,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.